Logo

Interpace Biosciences

Interpace Biosciences Q1 Revenues Up 8 Percent

The company attributed the revenue increase to improved performance in its clinical services business and increased reimbursement rates for its cancer tests.

Interpace Biosciences to Review Strategic Alternatives

The company, which was recently delisted from the Nasdaq, began a reorganization earlier this year in order to cut $7.2 million in annual costs.

Interpace Biosciences Q4 Revenues More Than Double

The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.

Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring

The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.

Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker

Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management. 

Jan 20, 2021

Interpace Bio Q3 Revenues Rise 6 Percent

Oct 20, 2020

Interpace Biosciences Q2 Revenues Decline 14 Percent

Jun 26, 2020

Interpace Biosciences Q1 Revenues Rise 53 Percent

Apr 23, 2020

Interpace Biosciences Q4 2019 Revenues Drop 29 Percent, Miss Analyst Predictions

Jan 13, 2020

Interpace Biosciences to Sell $20M in Preferred Stock, Plans Reverse Stock Split

Jan 6, 2020

Interpace Biosciences, University of North Carolina Launch Barrett's Esophagus Study

Dec 20, 2019

Interpace Biosciences Expanding Beyond Dx, Cancer With Acquisition, Name Change
Premium

Nov 13, 2019

Interpace Diagnostics Reports 33 Percent Q3 Revenue Growth; Changes Name to Interpace Biosciences

Oct 25, 2019

Cancer Genetics Settles Failed Merger Deal With NovellusDx; Receives $6M From Interpace

Oct 17, 2019

Interpace Diagnostics Closes $13M Financing Investment

Sep 30, 2019

Interpace Diagnostics Signs Thyroid Cancer Test Coverage Deals With Three BCBS Plans

Sep 16, 2019

Interpace Diagnostics, Genecast Biotechnology Ink Worldwide Research Services Agreement

Aug 13, 2019

Interpace Diagnostics Q2 Revenues Climb 14 Percent

Jul 31, 2019

Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan

Jul 29, 2019

Interpace Diagnostics Thyroid Assays Covered In-Network by Blue Shield of California

Jul 22, 2019

Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

Jul 18, 2019

Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making

Jul 15, 2019

Interpace Dx Acquires Cancer Genetics' Biopharma Services

Jun 20, 2019

Interpace Diagnostics Thyroid Assays Covered by Independence Blue Cross

May 13, 2019

Interpace Diagnostics Q1 Revenues Rise 25 Percent

Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.